ANDREW GUGGENHIME
CIK 1230724 · PRESIDENT AND CFO · last filed 2026-03-11
ANDREW GUGGENHIME is a PRESIDENT AND CFO who has filed 81 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider had shares withheld for taxes covering $60.6K of PCVX on Mar 11, 2026. Across all open-market trades the lifetime net is −$19.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $8.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$8.50M
6
81
-$19.04M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCVX | PRESIDENT AND CFO | 166,245 | $47.46 | $7.89M | -$17.06M | 46 | 2026-03-11 |
| CRBU | Director | — | $1.59 | — | $0 | 5 | 2026-02-20 |
| Metacrine, Inc. (MTCR) Delisted | Director | — | $0.49 | — | $0 | 2 | 2022-09-06 |
| DERM | CFO | 42,159 | $6.34 | $267.3K | -$1.98M | 15 | 2019-08-19 |
| FACT | SVP & CFO | 32,090 | $10.65 | $341.8K | $0 | 5 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | SVP & Chief Financial Officer | 13,255 | — | — | $0 | 5 | 2008-12-19 |
Recent Filings
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-11 | PCVX | Tax (F) | −1,021 | -$60.6K | EDGAR |
| 2026-03-02 | PCVX | Mixed | +42,957 | -$118.2K | EDGAR |
| 2026-02-20 | CRBU | Grant (A) | — | $0 | EDGAR |
| 2026-01-16 | PCVX | Gift (G) | — | $0 | EDGAR |
| 2025-09-10 | PCVX | Tax (F) | −2,890 | -$93.7K | EDGAR |
| 2025-09-04 | PCVX | Tax (F) | −5,080 | -$160.3K | EDGAR |
| 2025-04-09 | PCVX | Exer (M) | +4,777 | $100.0K | EDGAR |
| 2025-03-03 | PCVX | Mixed | +17,682 | -$367.4K | EDGAR |
| 2025-02-21 | CRBU | Grant (A) | — | $0 | EDGAR |
| 2025-02-19 | PCVX | Mixed | — | -$628.0K | EDGAR |